Genomic instability caused by BRCA1/2 deficiency leads to a higher neoantigen load and tumor mutational burden (TMB), which constitute an immune activation signature with a higher level of tumor infiltrating lymphocytes (TILs). Here, BRCA1 is linked to neoplasm.